Evidence map›Paper›PMID 40808297›Full record

ArticleNucleic acids research2025

PAM-interacting domain turn-helix 51 motifs can improve Cas9-SpRY activity.

Reto Eggenschwiler, Thomas Hoffmann, Oleg Dmytrenko, Mika Opitz, Marlene Ackel-Zakour, Pascal Wang, Shannon A McCallan, Mariane Fráguas-Eggenschwiler, Heiner Niemann, Atanas Patronov and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Reto EggenschwilerResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0003-3588-7847
Thomas HoffmannMolecular Systems Biology Unit, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
Oleg DmytrenkoHelmholtz Institute for RNA-based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.
Mika OpitzResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Marlene Ackel-ZakourResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Pascal WangResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.ORCID 0009-0004-0102-8133
Shannon A McCallanResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Mariane Fráguas-EggenschwilerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Heiner NiemannDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.
Atanas PatronovDiscovery Sciences, R&D, AstraZeneca Gothenburg, 43183 Mölndal, Sweden.ORCID 0000-0002-9797-6573
Chase L BeiselHelmholtz Institute for RNA-based Infection Research, Helmholtz Centre for Infection Research, 97080 Würzburg, Germany.ORCID 0000-0003-0650-9943
Tobias CantzResearch Group Translational Hepatology and Stem Cell Biology, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, 30625 Hannover, Germany.

Funding

European Research Council Consolidator 865973German Federal Ministry for Education and Research 01GM2204CGerman Federal Ministry for Education and Research 01GP2205CInstitute LOMMinistry of Science and Culture of Lower Saxony ZN3440
6 · The paper itself

Abstract

Cas9-SpRY is an engineered variant of the Streptococcus pyogenes Cas9 with relaxed PAM recognition, which can technically be utilized at any target in the genome but some targets are addressed with low efficiency. Here, we show that a previously unexplored motif at the turn and beginning of α-helix 51 (TH51) can be engineered to improve both nuclease and prime-editing activity of Cas9-SpRY. Interaction of the lysine-rich PID loop 2 (PL2) with the target DNA downstream of the PAM (post-PAM) mediates initiation of R-loop formation and subsequent cleavage yet it was unclear if other regions of the PID engage with post-PAM as well. To this end, the NAAN-PAM-targeting iSpyMac hybrid nuclease, which lacks all lysine residues in PL2, was compared with Cas9-SpRY at identical targets using molecular dynamics simulation and in cell culture models, uncovering four crucial post-PAM-interacting lysines in TH51 and TH53 of iSpyMac. Ectopic insertion of a lysine-rich PL2 into iSpyMac boosted its nuclease and prime-editing activities and, in turn, Cas9-SpRY benefited from certain lysine-rich TH51 motifs. Specifically, TH51 from an uncultured Abiotrophia Cas9 species boosted overall Cas9-SpRY activity. Together, this study demonstrates that engineering of post-PAM interacting motifs opens new avenues for the design of advanced CRISPR enzymes.

Indexed as

Bacterial ProteinsCRISPR-Associated Protein 9CRISPR-Cas SystemsDNADNA CleavageGene EditingHEK293 CellsHelix-Turn-Helix MotifsHumansLysineMolecular Dynamics SimulationNucleotide MotifsProtein EngineeringStreptococcus pyogenesBacterial ProteinsCas9 endonuclease Streptococcus pyogenesCRISPR-Associated Protein 9DNALysine

Identifiers

PMID40808297
PMCPMC12350091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.